Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

NCT05929066 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05929066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05929066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 10, 2023
Completion date
April 30, 2026
Enrollment
2,335 (actual)
Sites
134

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, obstructive sleep apnea, osteoarthritis, knee, overweight